NIH Funding Opportunities

Subscribe to NIH Funding Opportunities feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 5 hours 57 min ago

Notice of Clarification to PAR-19-064, "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)"

Thu, 09/26/2019 - 09:58
Notice NOT-DA-19-077 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Findings of Research Misconduct

Thu, 09/26/2019 - 07:17
Notice NOT-OD-19-140 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Limited Competition: Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Management Center (CPDPC-CDMC) (U01 Clinical Trial Optional)

Thu, 09/26/2019 - 01:06
Funding Opportunity RFA-DK-19-504 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is a limited invitation for U01 application for one Coordination and Data Management Center (CDMC) to continue the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Clinical Centers are being solicited via RFA-DK-19-009 "Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CCs) (U01) Clinical trial optional)". The CDMC along with CCs will be expected to share results freely within Consortium and to continue the trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the Consortium members (see https://cpdpc.mdanderson.org/clinicalstudies.html).
Categories: Science RSS Feeds

Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CPDPC-CCs) (U01 Clinical Trial Optional)

Thu, 09/26/2019 - 01:06
Funding Opportunity RFA-DK-19-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Coordination and Data Management Center (CDMC) are being solicited via RFA-DK-19-504 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CDMC) (U01 Clinical Trial Optional)". To effectively contribute to the ongoing CPDPC clinical studies, each CC applicant should include researchers and clinicians with multi-disciplinary expertise to match the objectives of the CPDPC (see https://cpdpc.mdanderson.org/clinicalstudies.html). Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the CCs.
Categories: Science RSS Feeds

Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, Analysis, and Scientific Outreach (UM1 Clinical Trial Not Allowed)

Wed, 09/25/2019 - 11:57
Funding Opportunity RFA-DA-20-027 from the NIH Guide for Grants and Contracts. To establish a Data Center to coordinate and analyze single cell and other molecular data sets generated by Single Cell Opioid Responses in the Context of HIV (SCORCH) and other NIDA-funded HIV and substance use disorder projects and to make the data findable, accessible, interoperable, and reusable (FAIR) to enable secondary analyses by the scientific community.
Categories: Science RSS Feeds

Notice of Special Interest: Nutrigenetics and Nutrigenomics Approaches for Nutrition Research

Wed, 09/25/2019 - 11:07
Notice NOT-DK-19-019 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Notice to Add a Receipt Date to PAR-19-374 Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)

Wed, 09/25/2019 - 00:06
Notice NOT-AG-19-046 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Tobacco Regulatory Science (R01 Clinical Trial Optional)

Tue, 09/24/2019 - 08:15
Funding Opportunity RFA-OD-19-028 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this FOA will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
Categories: Science RSS Feeds

Limited Competition: Specialized Centers of Excellence on Environmental Health Disparities Research (P50)

Mon, 09/23/2019 - 10:47
Funding Opportunity RFA-MD-20-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from eligible institutions of higher education for specialized center grants to support multidisciplinary research, research capacity building, and community-engaged research activities focused on understanding and reducing or eliminating environmental health disparities, defined as inequities in population health mediated by disproportionate adverse exposures associated with the physical, chemical, social and built environments.
Categories: Science RSS Feeds

Limited Competition: Pediatric Brain Tumor Consortium (UM1 Clinical Trials Required)

Mon, 09/23/2019 - 10:09
Funding Opportunity RFA-CA-19-059 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is intended to continue support for the Pediatric Brain Tumor Consortium (PBTC). This Limited-Competition FOA solicits a single application from the current PBTC awardee. The PBTC was conceived as a dedicated clinical trials organization able to translate innovative therapies from the laboratory to early phase clinical testing so that treatment for primary brain tumors in children can be improved. The importance of the PBTC is highlighted by the continuing high mortality rate among some common brain tumors occurring in children [e.g., diffuse intrinsic pontine gliomas (DIPG), malignant supratentorial gliomas, and biologically high-risk medulloblastomas and ependymomas] and the functional impediments apparent in a large proportion of children surviving current therapies. The PBTC is designed to fill a unique niche in the NIH pediatric brain tumor research portfolio through its ability to translate multiple innovative therapies from the laboratory to early phase clinical testing.
Categories: Science RSS Feeds

Pages